89Bio, Inc. Stock Price, News & Analysis

89bio, a clinical-stage biopharmaceutical company, has announced that additional data on pegozafermin for treating non-alcoholic steatohepatitis (NASH) will be presented at the EASL International Liver Congress™ 2022 in London from June 22-26, 2022. Key presentations include:

• Abstract 3535: Improved liver histology and metabolic profile.
• Abstract 3654: Significant metabolic benefits alongside liver improvements.
• Abstract 1520: Pharmacokinetics of BIO89-100 in NASH patients.

Presentations are on June 25, 2022.

89bio, Inc. (Nasdaq: ETNB) reported Q1 2022 financial results, showing a net loss of $25.6 million, up from $14.8 million in Q1 2021, primarily due to increased R&D and G&A expenses. The company aims to report topline data from its ENTRIGUE trial for severe hypertriglyceridemia (SHTG) in Q2 2022 and complete enrollment for its ENLIVEN trial for NASH by Q3 2022. As of March 31, 2022, 89bio held $126.1 million in cash, sufficient to fund operations into the second half of 2023.

89bio, a clinical-stage biopharmaceutical company focused on innovative therapies for liver and cardio-metabolic diseases, will participate in several investor conferences in May 2022. Key events include:

• BofA Securities Healthcare Conference on May 10, 2022, at 4:20 p.m. EST.
• RBC Capital Markets Global Healthcare Conference on May 18, 2022, at 10:30 a.m. EST.
• H.C. Wainwright Global Investment Conference on May 24, 2022, starting at 7:00 a.m. EST.

Webcasts of these presentations will be available on 89bio’s investor website.

89bio to Host KOL Webinar on Severe Hypertriglyceridemia

SAN FRANCISCO, April 26, 2022 – 89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), has announced a webinar scheduled for May 4, 2022, at 11:00 a.m. PT/2:00 p.m. ET. The event will feature presentations from renowned experts Harold Bays, MD, and Deepak L. Bhatt, MD, covering the treatment landscape for severe hypertriglyceridemia (SHTG) and the ENTRIGUE Phase 2 clinical trial of 89bio’s candidate pegozafermin. A Q&A session will also be included, emphasizing the clinical and regulatory development pathway for this innovative therapy.

89bio reported significant advancements in its clinical programs, revealing positive topline results from cohort 7 in the Phase 1b/2a NASH trial for pegozafermin. The data showed that 74% of patients achieved a 2-point or greater improvement in NAFLD Activity Score. The company anticipates topline data from the ENLIVEN Phase 2b NASH trial in the first half of 2023 and has closed enrollment in the ENTRIGUE trial, with results expected in Q2 2022. Financially, the company reported a net loss of $90.1 million for 2021, an increase attributed to higher R&D and G&A expenses.

89bio, Inc. (Nasdaq: ETNB) announced the appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors. Dr. Atkinson, with over 20 years of expertise in biopharmaceutical development and manufacturing, previously held senior roles at Vertex and Bristol Myers Squibb. CEO Rohan Palekar emphasized Atkinson’s valuable experience in optimizing manufacturing and commercializing therapies. This comes after promising data from the Phase 1b/2a study of 89bio's lead candidate, pegozafermin, targeting liver diseases like NASH and SHTG.

89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced its participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 12:00 PM ET. The management team will engage in a fireside chat and one-on-one investor meetings. A presentation will be available via the conference portal and archived on its website.

89bio, focused on therapies for liver and cardio-metabolic diseases, announced positive results from a Phase 1b/2a study of pegozafermin for treating NASH. In an expansion cohort of 20 patients, 63% achieved a 2-point improvement in NAS without worsening fibrosis, with 32% showing NASH resolution. The treatment also showed significant changes in liver health and cardio-metabolic markers, with pegozafermin being generally well tolerated. The ongoing Phase 2b ENLIVEN trial is expected to provide further insights, with results anticipated in the first half of 2023.

89bio, Inc. (Nasdaq: ETNB) recently presented findings from the Phase 1b/2a study of BIO89-100 at The Liver Meeting 2021, revealing a significant average reduction of 11.8% in spleen volume among NASH patients. This post-hoc analysis establishes a correlation between liver fat reduction and decreased spleen volume, suggesting improved portal blood flow as a mechanism. The oral presentation was recognized by the AASLD as a key presentation at the event. With promising preliminary data, 89bio aims to further explore BIO89-100's therapeutic potential for NASH.